The role of sentinel lymph node biopsy (SLNB) in the management of ductal carcinoma in situ (DCIS) is controversial and merits scrutiny ([@pkz052-B1]). Ongoing campaigns challenge the use of SLNB for patients with small breast cancer, raising doubt for its use in patients with DCIS, whereas proponents of SLNB cite concerns that occult disease may not be detected histologically ([@pkz052-B4],[@pkz052-B5]). An Agency for Healthcare Research and Quality--funded systematic review documented evidence gaps regarding the benefits and harms of SLNB in the management of DCIS ([@pkz052-B6]). Research after this review indicated that SLNB was not associated with breast cancer mortality ([@pkz052-B7]), a positive sentinel lymph node in the setting of DCIS did not affect survival ([@pkz052-B8]), and short-term side effects were increased with SLNB ([@pkz052-B9]). However, these studies were limited in scope and methodology, underpowered ([@pkz052-B7]), examined an SLNB cohort from a single institution ([@pkz052-B8]), and did not examine long-term impacts ([@pkz052-B9]). Given that SLNB use has increased from 7.2% to 39.4% among patients with DCIS who undergo breast-conserving surgery (BCS) ([@pkz052-B10]), it is critical to determine the associations between long-term outcomes and SLNB use for this population.

This retrospective cohort study used the Surveillance, Epidemiology, and End Results (SEER)-Medicare database to identify women (aged 67--94 years) diagnosed with DCIS between 2001 and 2013 who received BCS in the first 6 months after diagnosis and did not undergo mastectomy within 9 months postdiagnosis ([Supplementary Appendix](#sup1){ref-type="supplementary-material"} Figure 1, available online) ([@pkz052-B11]). SLNB was identified using Healthcare Common Procedure Coding System codes 38500, 38525, 38790, 38792, 38900, 78195, A9520, and G8878 ([@pkz052-B9],[@pkz052-B12]). Primary outcomes, suggested by patient and professional advisory committees, included treated recurrence (subsequent mastectomy after 9 months of DCIS diagnosis for the same DCIS primary) ([@pkz052-B17]), incident ipsilateral invasive breast cancer (IBC) occurrence (IBC diagnosis in the same breast), and breast cancer-specific mortality. Treated recurrence and breast cancer-specific mortality were followed through December 2014 and ipsilateral IBC occurrence through December 2013.

Of 12 776 women with DCIS, 1992 (15.6%) underwent SLNB (median follow-up, 69 months). Women who underwent SLNB tended to be younger, white (*P* = .007), diagnosed in recent years, and estrogen receptor positive and have comedonecrosis or higher-grade, larger (\>2 cm) tumors (*P*\<.001, unless specified) ([Supplementary Appendix Table 1](#sup1){ref-type="supplementary-material"}, available online). To account for potential treatment selection bias, a 1:2 Mahalanobis matching approach was used by selecting the two best non-SLNB patient matches for each SLNB patient ([@pkz052-B18]). Matching variables included age, tumor grade, tumor size, hormone receptor status, year of diagnosis, SEER registry site, and geographic region. Missing values of each variable were categorized. All 1992 women who underwent SLNB were successfully matched with 3965 non-SLNB controls (1973 women had two controls, 19 women had one). Baseline characteristics between patients with and without SLNB were well balanced, with standardized differences less than 10 ([Supplementary Appendix Table 2](#sup1){ref-type="supplementary-material"}, available online) ([@pkz052-B21]).

###### 

Unadjusted study outcomes by use of SLNB

  Outcomes                                        Before matching   After matching                                  
  ---------------------------------------------- ----------------- ---------------- ------ ------------ ----------- ------
  Mastectomy[†](#tblfn2){ref-type="table-fn"}       403 (3.7%)        78 (3.9%)     .700    145 (3.7%)   78 (3.9%)   .620
  Ipsilateral[‡](#tblfn3){ref-type="table-fn"}      216 (2.0%)        27 (1.4%)     .052    67 (1.7%)    27 (1.4%)   .329
  Breast cancer mortality                           116 (1.1%)        19 (1.0%)     .625    36 (0.9%)    19 (1.0%)   861

\**P* values were calculated by Pearson χ^2^ tests for differences in the proportion of patients with a given outcome between patients with and without use of SLNB. DCIS = ductal carcinoma in situ; SEER = Surveillance, Epidemiology, and End Results; SLNB = sentinel lymph node biopsy; N = number of study cohorts with a corresponding outcome in a group.

Defined by the receipt of mastectomy after 9 months of a DCIS diagnosis.

Ipsilateral invasive breast cancer occurrence after 9 months of a DCIS diagnosis, per SEER reports.

###### 

Unadjusted and adjusted hazard ratios (99% confidence interval) for the associations of SLNB and study outcomes

  Outcomes                                        Unadjusted HR (99% CI)  *P*     Adjusted\* HR (99% CI)  *P*
  ---------------------------------------------- ------------------------ ------ ------------------------ ------
  Mastectomy[†](#tblfn4){ref-type="table-fn"}      1.10 (0.77 to 1.57)    .509     1.17 (0.81 to 1.69)    .265
  Ipsilateral[‡](#tblfn5){ref-type="table-fn"}     0.84 (0.54 to 1.31)    .436     0.91 (0.50 to 1.65)    .673
  Breast cancer mortality                          1.08 (0.52 to 2.22)    .795     1.13 (0.54 to 2.35)    .674

Estimates were derived from competing risk Cox regression models among 5957 matched female patients with DCIS breast cancer from Mahalanobis matching ([Table 1](#pkz052-T1){ref-type="table"}). Models were also adjusted for the following variables: presence of physician visits, any hospitalization 3--24 months before DCIS diagnosis, use of preoperative breast magnetic resonance imaging, surgeon's operation volume, and receipt of radiation therapy. CI = confidence interval; DCIS = ductal carcinoma in situ; HR = hazard ratio; SEER = Surveillance, Epidemiology, and End Results; SLNB = sentinel lymph node biopsy.

Defined by receipt of mastectomy after 9 months of a DCIS diagnosis. Ipsilateral breast tumor recurrence after 9 months of a DCIS diagnosis, per SEER reports.

Cox proportional hazard models were applied to the Mahalanobis-matched cohort to estimate the associations between SLNB and outcomes, controlling for physician visits, hospitalizations, preoperative breast magnetic resonance imaging, surgeon volume, and receipt of radiation therapy. The proportional hazard assumption was tested and satisfied using the Therneau and Grambsch method. Acknowledging that patients who undergo SLNB might be healthier than those who do not, a competing-risk model using death by other causes was employed. Statistical significance was defined as *P* less than .01, two-sided, using χ^2^ tests or log-rank tests.

After Mahalanobis matching, patients with and without SLNB did not differ statistically significantly regarding treated recurrence (3.9% vs 3.7%, *P* = .62), ipsilateral invasive occurrence (1.4% vs 1.7%, *P* = .33), or breast cancer mortality (1.0% vs 0.9%, *P* = .86) ([Table 1](#pkz052-T1){ref-type="table"}). Competing-risk Cox proportional hazard models confirmed that SLNB use was not associated with a decrease in treated recurrence (adjusted hazard ratio \[AHR\] = 1.17, 99% CI = 0.81 to 1.69, *P* = .27), ipsilateral IBC occurrence (AHR = 0.91, 99% CI = 0.50 to 1.65, *P* = .67), or breast cancer mortality (AHR = 1.13, 99% CI = 0.54 to 2.35, *P* = .67) ([Table 2](#pkz052-T2){ref-type="table"}).

This study was limited to patients aged 67--94 years and may not be generalizable to a younger population. Although the sample comprises beneficiaries enrolled in Medicare fee-for-service programs, it would be surprising if the outcomes attributed to SLNB differed among Medicare Part C beneficiaries. Further analysis on the benefits of SLNB in DCIS with high-risk features is needed. The primary outcomes neither single out axillary recurrence nor include distant relapse, which merit investigation. Additionally, ipsilateral IBC occurrence was derived from the SEER database and may be underreported for patients with a prior DCIS diagnosis, although it is unlikely that reporting would differ because of SLNB. Although we applied Mahalanobis matching and competing-risk models to reduce bias, this observational study could not establish a strong causal inference. We acknowledge that we were unable to control for unobserved confounding factors, such as obesity, endocrine therapy status, postsurgical margin status, presence of a mass lesion, and provider's treatment preference.

Because our cohort was limited to patients who had a final diagnosis of DCIS, patients who were initially diagnosed with DCIS but were later upstaged to node-positive cancer due to SLNB were excluded in the SLNB group. In contrast, the non-SLNB group may have had undetected IBC; thus, this group (compared with the SLNB group) would have a higher risk of ipsilateral IBC occurrence. Although our study design favors the SLNB group in our cohort, we still found that rates of IBC were similar in both arms, suggesting that SLNB could be safely omitted.

SLNB has become the preferred method of axillary staging for patients with IBC; the proportion of patients who undergo SLNB is a quality metric for early-stage IBC care ([@pkz052-B22],[@pkz052-B23]). The inclusion of this quality measure in the Centers for Medicare & Medicaid Services' Merit-based Incentive Payment System has financially motivated providers to perform SLNB ([@pkz052-B24]). This increasing trend is a vivid example of "indication creep," promoting the use of an intervention outside the approved indication or target population ([@pkz052-B25]). Patients and surgeons may prefer SLNB if it does not reduce breast cancer mortality but could decrease local or regional recurrences, which could be indications for subsequent undesirable treatments. Therefore, organizations that promote quality for breast cancer care should emphasize the differences between invasive cancer and DCIS, referring to the two distinct SLNB quality measures simultaneously. With increased diagnoses of DCIS, determining the optimal clinical approach to treatment while minimizing side effects is important. Our study adds to the supporting evidence of current treatment guidelines that surgeons should avoid SLNB for women age 67--94 years with DCIS who undergo BCS as their initial treatment.
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